Are you Dr. Viglianti?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000
Summary
- Dr. Benjamin Viglianti, MD is a board certified nuclear medicine physician in Ann Arbor, Michigan. He is currently licensed to practice medicine in Michigan. He is affiliated with University of Michigan Medical Center and Trinity Health Livonia Hospital.
Education & Training
University of MichiganResidency, Radiology-Diagnostic, 2010 - 2014
Trinity Health Ann Arbor HospitalResidency, Internal Medicine, 2009 - 2010
Duke University School of MedicineClass of 2009
Certifications & Licensure
MI State Medical License 2009 - 2025- American Board of Nuclear Medicine Nuclear Medicine
- American Board of Radiology Diagnostic Radiology
Clinical Trials
- Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1) Start of enrollment: 2021 Jan 18
- Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4) Start of enrollment: 2021 Nov 01
Publications & Presentations
PubMed
- Towards a General Method for Using Cyclotron-Produced Ga68 to Manufacture Clinical and Research Ga68 Tracers.Ivan E Wang, Kevin Cheng, Allen F Brooks, Peter J H Scott, Benjamin L Viglianti
Molecules. 2024-11-19 - Molecular imaging for non-invasive risk stratification of renal masses.Steven P Rowe, Md Zobaer Islam, Benjamin Viglianti, Lilja B Solnes, Ezra Baraban
Diagnostic and Interventional Imaging. 2024-09-01 - 3AcFNP-59 for Positron Emission Tomography Imaging of Cholesterol Trafficking and Utilization.Allen F Brooks, Jason A Witek, Wade P Winton, Jenelle Stauff, Bradford Henderson
ACS Medicinal Chemistry Letters. 2024-08-08
Press Mentions
Post-ASCO News Alert: Novartis’ Lu-PSMA Early Uptake in Castration-Resistant Prostate Cancer May Be Stalled by Radiopharmaceutical Logistic Issues, Though ApprovableJune 25th, 2021- Myovant’s Phase III Relugolix Trial’s Cardiovascular Event Reduction Trend InconclusiveJune 18th, 2020
Consider PET/CT When Infectious Source Is a PuzzlerFebruary 11th, 2020- Join now to see all
